Diabetic neuropathy is common, under or misdiagnosed, and causes substantial morbidity with increased mortality. Defining and developing sensitive diagnostic tests for diabetic neuropathy is not only key to implementing earlier interventions but also to ensure that the most appropriate endpoints are employed in clinical intervention trials. This is critical as many potentially effective therapies may never progress to the clinic, not due to a lack of therapeutic effect, but because the endpoints were not sufficiently sensitive or robust to identify benefit. Apart from improving glycaemic control, there is no licensed treatment for diabetic neuropathy, however, a number of pathogenetic pathways remain under active study. Painful diabetic neuropathy is a cause of considerable morbidity and whilst many pharmacological and nonpharmacological interventions are currently used, only two are approved by the US Food and Drug Administration. We address the important issue of the ‘placebo effect’ and also consider potential new pharmacological therapies as well as nonpharmacological interventions in the treatment of painful diabetic neuropathy.
Abbott, C.A., Carrington, A.L., Ashe, H., Bath, S., Every, L.C., Griffiths, J. et al. (2002) The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med19: 377-384.
2.
Abuaisha, B.B., Costanzi, J.B. and Boulton, A.J. ( 1998) Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract39: 115-121.
3.
Agrawal, R.P., Goswami, J., Jain, S. and Kochar, D.K.(2009) Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract83: 371-378.
4.
Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T. et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med331: 1480-1487.
5.
Ametov, A.S., Barinov, A., Dyck, P.J., Hermann, R., Kozlova, N., Litchy, W.J. et al. (2003) The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid. Diabetes Care26: 770-776.
6.
Anderson, R.J., Freedland, K.E., Clouse, R.E. and Lustman, P.J. ( 2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care24: 1069-1078.
7.
Andersson, S. and Lundeberg, T. ( 1995) Acupuncture - from empiricism to science: functional background to acupuncture effects in pain and disease. Med Hypotheses45: 271-281.
8.
Andre-Obadia, N., Mertens, P., Gueguen, A., Peyron, R. and Garcia-Larrea, L. ( 2008) Pain relief by rTMS: differential effect of current flow but no specific action on pain subtypes. Neurology71: 833-840.
9.
Armstrong, D.G., Lavery, L.A., Fleischli, J.G. and Gilham, K.A. ( 1997) Is electrical stimulation effective in reducing neuropathic pain in patients with diabetes? J Foot Ankle Surg36: 260-263.
10.
Attal, N., Cruccu, G., Haanpaa, M., Hansson, P., Jensen, T.S., Nurmikko, T. et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol13: 1153-1169.
11.
Backonja, M.M., Irving, G. and Argoff, C. ( 2006) Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep10: 34-38.
12.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I. and Serpell, M.(2009) Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy . Curr Med Res Opin25: 1677-1687.
13.
Bernateck, M., Rolke, R., Birklein, F., Treede, R.D., Fink, M. and Karst, M. ( 2007) Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg105: 1148-1151, table of contents.
14.
Bevilacqua, M., Dominquez, L.J., Barrella, M. and Barbagallo, M. ( 2007) Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy . J Endocrinol Invest30: 944-947.
15.
Biesbroeck, R., Bril, V., Hollander, P., Kabadi, U., Schwartz, S., Singh, S.P. et al. (1995) A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther12: 111-120.
16.
Booth, J. and Young, M.J. ( 2000) Differences in the performance of commercially available 10-g monofilaments. Diabetes Care23: 984-988.
17.
Borckardt, J.J., Smith, A.R., Reeves, S.T., Weinstein, M., Kozel, F.A., Nahas, Z. et al. (2007) Fifteen minutes of left prefrontal repetitive transcranial magnetic stimulation acutely increases thermal pain thresholds in healthy adults. Pain Res Manag12: 287-290.
18.
Boucek, P., Havrdova, T., Voska, L., Lodererova, A., Saudek, F., Lipar, K. et al. (2005) Severe depletion of intraepidermal nerve fibers in skin biopsies of pancreas transplant recipients. Transplant Proc37: 3574-3575.
Bretin, S., Rogemond, V., Marin, P., Maus, M., Torrens, Y., Honnorat, J. et al. (2006) Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem98: 1252-1265.
21.
Bril, V. and Buchanan, R. ( 2004) Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care27: 2369-2375.
22.
Bril, V. and Buchanan, R.A. ( 2006) Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care29: 68-72.
23.
Bril, V., Toshiyuki, H., Tomioka, S. and Buchanan, R.(2009) Ranirestat for the management of diabetic sensorimotor polyneuropathy . Diabetes Care32: 1256-1260.
24.
Calcutt, N.A. and Backonja, M.M. ( 2007) Pathogenesis of pain in peripheral diabetic neuropathy . Curr Diab Rep7: 429-434.
25.
Carmeliet, P. ( 2003) Angiogenesis in health and disease. Nature Med9: 653-660.
Casellini, C.M., Barlow, P.M., Rice, A.L., Casey, M., Simmons, K., Pittenger, G. et al. (2007) A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care30: 896-902.
28.
Chalk, C., Benstead, T. and Moore, F. ( 2007) Aldose reductase inhibitors for the treatment of diabetic polyneuropathy (Review). The Cochrane Library4: 1-46.
29.
Challapalli, V., Tremont-Lukats, I.W., McNicol, E.D., Lau, J. and Carr, D.B. ( 2005) Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev4: CD003345.
30.
Chattopadhyay, M., Mata, M. and Fink, D.J. ( 2008) Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci28: 6652-6658.
31.
Chaudhry, V., Stevens, J.C., Kincaid, J. and So, Y.T. ( 2006) Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology66: 1805-1808.
32.
Chizh, B.A., O’Donnell, M.B., Napolitano, A., Wang, J., Brooke, A.C., Aylott, M.C. et al. (2007) The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans . Pain132: 132-141.
33.
Choi, J.S., Zhang, L., Dib-Hajj, S.D., Han, C., Tyrrell, L., Lin, Z. et al. (2009) Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. Exp Neurol216: 383-389.
34.
Chong, M.S. and Hester, J. ( 2007) Diabetic painful neuropathy: current and future treatment options. Drugs67: 569-585.
35.
Chow, R.T., Johnson, M.I., Lopes-Martins, R.A. and Bjordal, J.M.(2009) Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet374: 1897-1908.
36.
Christoph, T., Bahrenberg, G., De Vry, J., Englberger, W., Erdmann, V.A., Frech, M. et al. (2008) Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell Neurosci37: 579-589.
37.
Colbert, A.P., Wahbeh, H., Harling, N., Connelly, E., Schiffke, H.C., Forsten, C. et al. (2009) Static magnetic field therapy: a critical review of treatment parameters. Evid Based Complement Alternat Med6: 133-139.
38.
Conti, M., Peretti, E., Cazzetta, G., Galimberti, G., Vermigli, C., Pola, R. et al. (2009) Frequency-modulated electromagnetic neural stimulation enhances cutaneous microvascular flow in patients with diabetic neuropathy. J Diabetes Complications23: 46-48.
39.
Daousi, C., Benbow, S.J. and MacFarlane, I.A. ( 2005) Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med22: 393-398.
40.
de Leeuw, K., Kusumanto, Y., Smit, A.J., Oomen, P., van der Hoeven, J.H., Mulder, N.H. et al. (2008) Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product . Diabet Med25: 1241-1244.
41.
Deguchi, T., Hashiguchi, T., Horinouchi, S., Uto, T., Oku, H., Kimura, K. et al. (2009) Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabet Med26: 247-252.
42.
DeLellis, S.L., Carnegie, D.H. and Burke, T.J. ( 2005) Improved sensitivity in patients with peripheral neuropathy: effects of monochromatic infrared photo energy. J Am Podiatr Med Assoc95: 143-147.
43.
Demiot, C., Fromy, B., Saumet, J.L. and Sigaudo-Roussel, D. ( 2006) Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. Cardiovasc Res69: 245-252.
44.
Dib-Hajj, S.D., Binshtok, A.M., Cummins, T.R., Jarvis, M.F., Samad, T. and Zimmermann, K.(2009a) Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res Rev60: 65-83.
45.
Dib-Hajj, S.D., Black, J.A. and Waxman, S.G.(2009b) Voltage-gated sodium channels: therapeutic targets for pain. Pain Med10: 1260-1269.
46.
Du, X., Edelstein, D. and Brownlee, M. ( 2008) Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia51: 1930-1932.
47.
Dubinsky, R.M. and Miyasaki, J.(2010) Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology74: 173-176.
48.
Dworkin, R.H., Katz, J. and Gitlin, M.J. ( 2005) Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology65(12 Suppl 4): S7-S19.
49.
Dworkin, R.H., O’Connor, A.B., Backonja, M., Farrar, J.T., Finnerup, N.B., Jensen, T.S. et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain132: 237-251.
50.
Dyck, P.J., Norell, J.E., Tritschler, H., Schuette, K., Samigullin, R., Ziegler, D. et al. (2007) Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care30: 2619-2625.
51.
Egede, L.E., Zheng, D. and Simpson, K. ( 2002) Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care25: 464-470.
52.
Errington, A.C., Stohr, T., Heers, C. and Lees, G. ( 2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol73: 157-169.
53.
Eshkevari, L. ( 2003) Acupuncture and pain: a review of the literature. AANA J71: 361-370.
54.
Eshkevari, L. and Heath, J. ( 2005) Use of acupuncture for chronic pain: optimizing clinical practice. Holist Nurs Pract19: 217-221.
55.
Estacion, M., Harty, T.P., Choi, J.S., Tyrrell, L., Dib-Hajj, S.D. and Waxman, S.G. ( 2009) A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann Neurol66: 862-866.
56.
Evans, J.L., Heymann, C.J., Ira, D. and Gavin, L.A. ( 2002) Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocrine Pract8: 29-35.
57.
Faghihi, H., Roohipoor, R., Mohammadi, S.F., Hojat-Jalali, K., Mirshahi, A., Lashay, A. et al. (2008) Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol18: 941-948.
58.
Faivre, A., Franques, J., De Paula, A.M., Gutierrez, M., Bret, S., Aubert, S. et al. (2010) Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. J Neurol Sci291(1-2): 103-106.
59.
Fischer, T.Z., Gilmore, E.S., Estacion, M., Eastman, E., Taylor, S., Melanson, M. et al. (2009) A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol65: 733-741.
60.
Forst, T., Nguyen, M., Forst, S., Disselhoff, B., Pohlmann, T. and Pfutzner, A. ( 2004) Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device . Diabetes Nutr Metab17: 163-168.
61.
Foster, A.V., Eaton, C., McConville, D.O. and Edmonds, M.E. ( 1994) Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabet Med11: 768-772.
62.
Freeman, R., Durso-Decruz, E. and Emir, B. ( 2008) Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care31: 1448-1454.
63.
Freeman, R., Raskin, P., Hewitt, D.J., Vorsanger, G.J., Jordan, D.M., Xiang, J. et al. (2007) Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin23: 147-161.
64.
Fromy, B., Abraham, P., Bouvet, C., Bouhanick, B., Fressinaud, P. and Saumet, J.L. ( 2002) Early decrease of skin blood flow in response to locally applied pressure in diabetic subjects. Diabetes51: 1214-1217.
65.
Galiano, R.D., Tepper, O.M., Pelo, C.R., Bhatt, K.A., Callaghan, M., Bastidas, N. et al. (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol164: 1935-1947.
66.
Gavva, N.R., Treanor, J.J., Garami, A., Fang, L., Surapaneni, S., Akrami, A. et al. (2008) Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain136: 202-210.
67.
Gianturco, V., Bellomo, A., D’Ottavio, E., Formosa, V., Iori, A., Mancinella, M. et al. (2009) Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction?Arch Gerontol Geriatr49: 129-133.
68.
Gilbert, R.E., Vranes, D., Berka, J.L., Kelly, D.J., Cox, A., Wu, L.L. et al. (1998) Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest78: 1017-1027.
69.
Goldberg, N. ( 2005) Monochromatic infrared photo energy and DPN. Diabetic Microvasc Complications Today March/April: 30-32.
70.
Goldstein, D.J., Lu, Y., Detke, M.J., Lee, T.C. and Iyengar, S. ( 2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain116: 109-118.
71.
Gore, M., Dukes, E., Rowbotham, D.J., Tai, K.S. and Leslie, D. ( 2007) Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings . Eur J Pain11: 652-664.
72.
Green, A.Q., Krishnan, S., Finucane, F.M. and Rayman, G. ( 2010) Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care33: 174-176.
73.
Greenstein, A.S., Khavandi, K., Withers, S.B., Sonoyama, K., Clancy, O., Jeziorska, M. et al. (2009) Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation119: 1661-1670.
74.
Hamada, Y. and Nakamura, J. ( 2004) Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol3: 245-255.
75.
Hamza, M.A., White, P.F., Craig, W.F., Ghoname, E.S., Ahmed, H.E., Proctor, T.J. et al. (2000) Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care23: 365-370.
76.
Han, C., Dib-Hajj, S.D., Lin, Z., Li, Y., Eastman, E.M., Tyrrell, L. et al. (2009) Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation. Brain 132(Pt7): 1711-1722.
77.
Han, J.S. ( 2004) Acupuncture and endorphins. Neurosci Lett361: 258-261.
78.
Hanna, M., O’Brien, C. and Wilson, M.C. ( 2008) Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain12: 804-813.
79.
Harkless, L.B., DeLellis, S., Carnegie, D.H. and Burke, T.J. ( 2006) Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with monochromatic infrared photo energy - MIRE. J Diabetes Complications20: 81-87.
80.
Honda, K., Koguchi, M., Koga, K., Nakajima, K., Kobayashi, F., Migita, K. et al. (2007) Contribution of Ca(2+) -dependent protein kinase C in the spinal cord to the development of mechanical allodynia in diabetic mice. Biol Pharm Bull30: 990-993.
81.
Hossain, P., Sachdev, A. and Malik, R.A. ( 2005) Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet366: 1340-1343.
82.
Hotta, N., Akanuma, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M. et al. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care29: 1538-1544.
83.
Hotta, N., Sakamoto, N., Shigeta, Y., Kikkawa, R. and Goto, Y. ( 1996) Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. J Diabetes Complications10: 168-172.
84.
Hsu, D.T. ( 1996) Acupuncture. A review. Reg Anesth21: 361-370.
85.
Huang, E.A. and Gitelman, S.E. ( 2008) The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatric Diabetes9: 69-73.
86.
Hung, J.W., Liou, C.W., Wang, P.W., Yeh, S.H., Lin, L.W., Lo, S.K. et al. (2009) Effect of 12-week tai chi chuan exercise on peripheral nerve modulation in patients with type 2 diabetes mellitus. J Rehabil Med41: 924-929.
87.
Irizarry, M.C.M., Webb, D.J.M., Ali, Z.P., Chizh, B.A.M., Gold, M.M.S.M.D., Kinrade, F.J.B. et al. (2009) Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain25: 469-476.
88.
Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Ahmed, E., Carrasquillo, K.G. et al. (2003) VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci44: 2155-2162.
89.
Jain, S.C., Uppal, A., Bhatnagar, S.O. and Talukdar, B. ( 1993) A study of response pattern of non-insulin dependent diabetics to yoga therapy. Diabetes Res Clin Pract19: 69-74.
90.
Jiang, H., Shi, K., Li, X., Zhou, W. and Cao, Y. ( 2006) Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Tradit Chin Med26: 8-12.
91.
Joshi, S.K., Honore, P., Hernandez, G., Schmidt, R., Gomtsyan, A., Scanio, M. et al. (2009) Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models. J Pain10: 306-315.
92.
Kamei, J., Mizoguchi, H., Narita, M. and Tseng, L.F. ( 2001) Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs10: 1653-1664.
93.
Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K. et al. (1998) Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus . J Clin Endocrinol Metab83: 859-862.
94.
Katz, J., Finnerup, N.B. and Dworkin, R.H. ( 2008) Clinical trial outcome in neuropathic pain: Relationship to study characteristics. Neurology70: 263-272.
95.
Kawai, T., Takei, I., Tokui, M., Funae, O., Miyamoto, K., Tabata, M. et al. (2009) Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N[var epsilon]-carboxymethyl lysine. J Diabetes Complications, in press.
96.
Kelly, K.G., Cook, T. and Backonja, M.M. ( 2005) Pain ratings at the thresholds are necessary for interpretation of quantitative sensory testing. Muscle Nerve32: 179-184.
97.
Khedr, E.M., Kotb, H., Kamel, N.F., Ahmed, M.A., Sadek, R. and Rothwell, J.C. ( 2005) Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain . J Neurol Neurosurg Psychiatry76: 833-838.
98.
Knotkova, H., Pappagallo, M. and Szallasi, A. ( 2008) Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain24: 142-154.
99.
Kumar, D. and Marshall, H.J. ( 1997) Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care20: 1702-1705.
100.
Kumar, K., Malik, S. and Demeria, D. ( 2002) Treatment of chronic pain with spinal cord stimulation versus alternative therapies: cost-effectiveness analysis. Neurosurgery51: 106-115, discussion 115-106.
101.
Kuwabara, S. and Misawa, S. ( 2008) Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies . Curr Mol Pharmacol1: 61-67.
102.
Lee, H.J., Lee, J.H., Lee, E.O., Kim, K.H., Lee, K.S., Lee, C.H. et al. (2009) Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model. Acupunct Electrother Res34: 27-40.
103.
Leonard, D.R., Farooqi, M.H. and Myers, S. ( 2004) Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care27: 168-172.
104.
Liu, L., Zhao, S.P., Wen, T., Zhou, H.N., Hu, M. and Li, J.X. ( 2008) Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients . Coron Artery Dis19: 145-151.
105.
Loseth, S., Stalberg, E., Jorde, R. and Mellgren, S.I. ( 2008) Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol255: 1197-1202.
106.
Ma, W. and Quirion, R. ( 2006) Targeting invading macrophage-derived PGE2, IL-6 and calcitonin gene-related peptide in injured nerve to treat neuropathic pain. Expert Opin Ther Targets10: 533-546.
107.
Madej, A., Buldak, L., Basiak, M., Szkrobka, W., Dulawa, A. and Okopien, B.(2009) The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther47: 686-694.
108.
Malhotra, V., Singh, S., Tandon, O.P., Madhu, S.V., Prasad, A. and Sharma, S.B. ( 2002) Effect of Yoga asanas on nerve conduction in type 2 diabetes . Indian J Physiol Pharmacol46: 298-306.
109.
Malik, R.A., Tesfaye, S., Newrick, P.G., Walker, D., Rajbhandari, S.M., Siddique, I. et al. (2005) Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia48: 578-585.
110.
Malik, R.A., Veves, A., Walker, D., Siddique, I., Lye, R.H., Schady, W. et al. (2001) Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol101: 367-374.
111.
Malik, R.A., Williamson, S., Abbott, C., Carrington, A.L., Iqbal, J., Schady, W. et al. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet352: 1978-1981.
112.
Mason, L., Moore, R.A., Derry, S., Edwards, J.E. and McQuay, H.J. ( 2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ328: 991.
113.
Max, M.B., Lynch, S.A., Muir, J., Shoaf, S.E., Smoller, B. and Dubner, R. ( 1992) Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med326: 1250-1256.
114.
McQuay, H.J. ( 2008) Placebo and control event rate, In: McQuay, H.J. et al. (eds). Systematic Reviews in Pain Research: Methodology Redefined, IASP Press : Seattle, WA, pp. 51-56.
115.
Mehra, S., Tavakoli, M., Kallinikos, P.A., Efron, N., Boulton, A.J., Augustine, T. et al. (2007) Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes . Diabetes Care30: 2608-2612.
116.
Miranda-Palma, B., Sosenko, J.M., Bowker, J.H., Mizel, M.S. and Boulton, A.J. ( 2005) A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. Diabetes Res Clin Pract70: 8-12.
117.
Mirshahi, A., Roohipoor, R., Lashay, A., Mohammadi, S.F., Abdoallahi, A. and Faghihi, H. ( 2008) Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial . Eur J Ophthalmol18: 263-269.
118.
Misawa, S., Kuwabara, S., Kanai, K., Tamura, N., Nakata, M., Sawai, S. et al. (2006) Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. Neurology66: 1545-1549.
119.
Mojaddidi, M., Quattrini, C., Tavakoli, M. and Malik, R.A. ( 2005) Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. Curr Diab Rep5: 417-422.
120.
Moore, R.A., Straube, S., Wiffen, P.J., Derry, S. and McQuay, H.J. ( 2009) Pregabalin for acute and chronic pain in adults. Cochrane Database Syst RevCD007076.
121.
Nayak, N.N. and Shankar, K. ( 2004) Yoga: a therapeutic approach. Phys Med Rehabil Clin N Am15: 783-798, vi.
122.
Nicholson, B.P. and Schachat, A.P. ( 2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol.
123.
Noble, M., Treadwell, J.R., Tregear, S.J., Coates, V.H., Wiffen, P.J., Akafomo, C. et al. (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev1: CD006605.
124.
Norcini, M., Vivoli, E., Galeotti, N., Bianchi, E., Bartolini, A. and Ghelardini, C.(2009) Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain146: 141-147.
125.
Oates, P.J. ( 2008) Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets9: 14-36.
126.
Orr, R., Tsang, T., Lam, P., Comino, E. and Singh, M.F. ( 2006) Mobility impairment in type 2 diabetes: association with muscle power and effect of Tai Chi intervention. Diabetes Care29: 2120-2122.
127.
Pawson, E.J., Duran-Jimenez, B., Surosky, R., Brooke, H.E., Spratt, S.K., Tomlinson, D.R. et al. (2009) Engineered zinc finger protein mediated VEGF-A activation restores deficient VEGF-A in sensory neurons in experimental diabetes . Diabetes.
128.
Polydefkis, M., Hauer, P., Sheth, S., Sirdofsky, M., Griffin, J.W. and McArthur, J.C. ( 2004) The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy . Brain127: 1606-1615.
129.
Prendergast, J.J., Miranda, G. and Sanchez, M. ( 2004) Improvement of sensory impairment in patients with peripheral neuropathy. Endocr Pract10: 24-30.
130.
Price, S.A., Dent, C., Duran-Jimenez, B., Liang, Y., Zhang, L., Rebar, E.J. et al. (2006) Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes55: 1847-1854.
131.
Qiang, X., Satoh, J., Sagara, M., Fukuzawa, M., Masuda, T., Miyaguchi, S. et al. (1998a) Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism47: 977-981.
132.
Qiang, X., Satoh, J., Sagara, M., Fukuzawa, M., Masuda, T., Sakata, Y. et al. (1998b) Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia41: 1321-1326.
133.
Quattrini, C., Jeziorska, M., Boulton, A.J. and Malik, R.A. ( 2008) Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care31: 140-145.
134.
Quattrini, C., Tavakoli, M., Jeziorska, M., Kallinikos, P., Tesfaye, S., Finnigan, J. et al. (2007) Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes56: 2148-2154.
135.
Quessy, S.N. and Rowbotham, M.C. ( 2008) Placebo response in neuropathic pain trials. Pain138: 479-483.
136.
Ramirez, M.A. and Borja, N.L. ( 2008) Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy28: 646-655.
137.
Rappaport, B.A. ( 2007) Current FDA policy on analgesic drug and biologic products development. In: 10th International Conference on the Mechanisms and Treatment of Neuropathic Pain.
138.
Raskin, J., Wang, F., Pritchett, Y.L. and Goldstein, D.J. ( 2006) Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Medicine7: 373-385.
139.
Rauck, R.L.M., Shaibani, A.M.D., Biton, V.M.D., Simpson, J.P. and Koch, B.P. ( 2007) Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain23: 150-158.
140.
Reja, A., Tesfaye, S., Harris, N.D. and Ward, J.D. ( 1995) Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med12: 307-309.
141.
Ropper, A.H., Gorson, K.C., Gooch, C.L., Weinberg, D.H., Pieczek, A., Ware, J.H. et al. (2009) Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol65: 386-393.
142.
Rowbotham, M.C., Goli, V., Kunz, N.R. and Lei, D. ( 2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain110: 697-706.
143.
Sagara, M., Satoh, J., Wada, R., Yagihashi, S., Takahashi, K., Fukuzawa, M. et al. (1996) Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia39: 263-269.
144.
Sahin, S., Karsidag, S., Ayalp, S., Sengul, A., Us, O. and Karsidag, K. ( 2009) Determination of nerve conduction abnormalities in patients with impaired glucose tolerance. Neurol Sci.
145.
Samii, A., Unger, J. and Lange, W. ( 1999) Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett262: 159-162.
146.
Satoh, J., Yagihashi, S. and Toyota, T. ( 2003) The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res4: 65-71.
147.
Schafers, M., Brinkhoff, J., Neukirchen, S., Marziniak, M. and Sommer, C. ( 2001) Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett310: 113-116.
148.
Scheffler, N.M., Sheitel, P.L. and Lipton, M.N. ( 1991) Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc81: 288-293.
149.
Schemmel, K.E., Padiyara, R.S. and D’Souza, J.J. ( 2009) Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications .
150.
Schratzberger, P., Schratzberger, G., Silver, M., Curry, C., Kearney, M., Magner, M. et al. (2000) Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nature Med6: 405-413.
151.
Schuessler, B. ( 2006) What do we know about duloxetine’s mode of action? Evidence from animals to humans. BJOG113: 5-9.
152.
Schwartzman, R.J., Chevlen, E. and Bengtson, K. ( 2003) Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med163: 1487-1488; author reply 1488.
153.
Selvarajah, D., Gandhi, R., Emery, C.J. and Tesfaye, S.(2010) A randomised placebo controlled double blind clinical trial of cannabis based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care33(1): 128-130.
154.
Sharma, S., Chopra, K. and Kulkarni, S.K. ( 2007) Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res21: 278-283.
155.
Sharma, S. and Sharma, N. ( 2008) Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. Ann Indian Acad Neurol11: 231-235.
156.
Shay, K., Moreau, R., Smith, E., Smith, A. and Hagen, T.(2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta1790: 1149-1160.
157.
Sheets, P.L., Heers, C., Stoehr, T. and Cummins, T.R. ( 2008) Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. J Pharmacol Exp Ther326: 89-99.
158.
Shrivastav, M. and Musley, S.(2009) Spinal cord stimulation for complex regional pain syndrome. Conf Proc IEEE Eng Med Biol Soc1: 2033-2036.
159.
Shweiki, D., Itin, A., Soffer, D. and Keshet, E. ( 1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature359: 843-845.
160.
Simpson, D.M., Brown, S. and Tobias, J. ( 2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology70: 2305-2313.
161.
Simpson, D.M., Estanislao, L., Brown, S.J. and Sampson, J. ( 2008) An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage35: 299-306.
162.
Smith, A.G., Howard, J.R., Kroll, R., Ramachandran, P., Hauer, P., Singleton, J.R. et al. (2005) The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci228: 65-69.
163.
Smith, A.G., Russell, J., Feldman, E.L., Goldstein, J., Peltier, A., Smith, S. et al. (2006) Lifestyle intervention for pre-diabetic neuropathy . Diabetes Care29: 1294-1299.
164.
Smith, A.G. and Singleton, J.R. ( 2008) Impaired glucose tolerance and neuropathy. Neurologist14: 23-29.
165.
Song, Z., Ultenius, C., Meyerson, B.A. and Linderoth, B.(2009) Pain relief by spinal cord stimulation involves serotonergic mechanisms: an experimental study in a rat model of mononeuropathy. Pain147: 241-248.
166.
Sorensen, L., Molyneaux, L. and Yue, D.K. ( 2006a) The level of small nerve fiber dysfunction does not predict pain in diabetic Neuropathy: a study using quantitative sensory testing. Clin J Pain22: 261-265.
167.
Sorensen, L., Molyneaux, L. and Yue, D.K. ( 2006b) The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care29: 883-887.
168.
Storkebaum, E., Diether, L. and Peter, C. ( 2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays26: 943-954.
169.
Strickland, M.E. ( 1997) Evaluation of bacterial growth with occlusive dressing use on excoriated skin in the premature infant. Neonatal Netw16: 29-35.
170.
Sumner, C.J., Sheth, S., Griffin, J.W., Cornblath, D.R. and Polydefkis, M. ( 2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology60: 108-111.
171.
Szallasi, A. and Blumberg, P.M. ( 1993) [3H]resiniferatoxin binding by the vanilloid receptor: species-related differences, effects of temperature and sulfhydryl reagents . Naunyn Schmiedebergs Arch Pharmacol347: 84-91.
172.
Szallasi, A. and Blumberg, P.M. ( 1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev51: 159-212.
173.
Takei, Y. and Laskey, R. ( 2008) Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol Med14: 381-388.
174.
Tandan, R., Lewis, G.A., Krusinski, P.B., Badger, G.B. and Fries, T.J. ( 1992) Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care15: 8-14.
175.
Tankova, T., Cherninkova, S. and Koev, D. ( 2005) Treatment for diabetic mononeuropathy with α-lipoic acid. Int J Clin Pract59: 645-650.
176.
Tavakoli, M., Kallinikos, P.A., Efron, N., Boulton, A.J. and Malik, R.A. ( 2007) Corneal sensitivity is reduced and relates to the severity of neuropathy in patients with diabetes. Diabetes Care30: 1895-1897.
177.
Tavakoli, M., Marshall, A., Pitceathly, R., Fadavi, H., Gow, D., Roberts, M.E. et al. (2010) Corneal confocal microscopy: A novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol223(1): 245-250.
178.
Tavakoli, M., Marshall, A., Thompson, L., Kenny, M., Waldek, S., Efron, N. et al. (2009) Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease. Muscle Nerve40: 976-984.
179.
Tesfaye, S., Watt, J., Benbow, S.J., Pang, K.A., Miles, J. and MacFarlane, I.A. ( 1996) Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet348: 1698-1701.
180.
The Capsaicin Study Group (1991) Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med151: 2225-2229.
181.
Topper, R., Foltys, H., Meister, I.G., Sparing, R. and Boroojerdi, B. ( 2003) Repetitive transcranial magnetic stimulation of the parietal cortex transiently ameliorates phantom limb pain-like syndrome. Clin Neurophysiol114: 1521-1530.
182.
Tremont-Lukats, I.W., Challapalli, V., McNicol, E.D., Lau, J. and Carr, D.B. ( 2005) Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg101: 1738-1749.
183.
Troy, T. ( 2002) The use of Opsite, Fixomull and Lycra ® in the management of diabetic neuropathic pain of the foot. Primary Intention10: 162-164,166-170.
184.
Turner, J.A., Deyo, R.A., Loeser, J.D., Von Korff, M. and Fordyce, W.E. ( 1994) The importance of placebo effects in pain treatment and research. JAMA271: 1609-1614.
185.
Uceyler, N., Rogausch, J.P., Toyka, K.V. and Sommer, C. ( 2007) Differential expression of cytokines in painful and painless neuropathies. Neurology69: 42-49.
186.
Uceyler, N. and Sommer, C. ( 2008) Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett437: 194-198.
187.
Umapathi, T., Tan, W.L., Loke, S.C., Soon, P.C., Tavintharan, S. and Chan, Y.H. ( 2007) Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve35: 591-598.
188.
Valdivia, J.M., Dellon, A.L., Weinand, M.E. and Maloney Jr, C.T. ( 2005) Surgical treatment of peripheral neuropathy: outcomes from 100 consecutive decompressions. J Am Podiatr Med Assoc95: 451-454.
189.
Vileikyte, L., Peyrot, M., Gonzalez, J.S., Rubin, R.R., Garrow, A.P., Stickings, D. et al. (2009) Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia52: 1265-1273.
190.
Vincent, A.M., Hayes, J.M., McLean, L.L., Vivekanandan-Giri, A., Pennathur, S. and Feldman, E.L.(2009) Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes58: 2376-2385.
191.
Vinik, A.I., Bril, V., Kempler, P., Litchy, W.J., Tesfaye, S., Price, K.L. et al. (2005) Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial . Clin Ther27: 1164-1180.
192.
Wang, C.P., Kao, C.H., Chen, W.K., Lo, W.Y. and Hsieh, C.L. ( 2008) A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis . J Altern Complement Med14: 833-839.
193.
Weintraub, M.I., Herrmann, D.N., Smith, A.G., Backonja, M.M. and Cole, S.P.(2009) Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil90: 1102-1109.
194.
Weintraub, M.I., Wolfe, G.I., Barohn, R.A., Cole, S.P., Parry, G.J., Hayat, G. et al. (2003) Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial . Arch Phys Med Rehabil84: 736-746.
195.
Wernicke, J.F., Pritchett, Y.L., D’Souza, D.N., Waninger, A., Tran, P., Iyengar, S. et al. (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology67: 1411-1420.
196.
Wiffen, P.J., Collins, S., McQuay, H.J., Carroll, D., Jadad, A. and Moore, R.A. ( 2010) Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev1: CD001133.
197.
Wiggin, T.D., Sullivan, K.A., Pop-Busui, R., Amato, A., Sima, A.A. and Feldman, E.L.(2009) Elevated triglycerides correlate with progression of diabetic neuropathy . Diabetes58: 1634-1640.
198.
Wong, G.Y. and Gavva, N.R.(2009) Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and set-backs. Brain Res Rev60: 267-277.
199.
Wymer, J.P.M., Simpson, J.P., Sen, D.P., Bongardt, S.M.S. and on behalf of the Lacosamide, S.P. (2009) Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain25: 376-385.
200.
Yalcin, B.M., Karahan, T.F., Ozcelik, M. and Igde, F.A. ( 2008) The effects of an emotional intelligence program on the quality of life and well-being of patients with type 2 diabetes mellitus. Diabetes Educ34: 1013-1024.
201.
Yoshida, S., Hirai, M., Suzuki, S., Awata, S. and Oka, Y.(2009) Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes. Psychiatry Clin Neurosci63: 65-72.
202.
Zelman, D.C., Brandenburg, N.A. and Gore, M. ( 2006) Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain22: 681-685.
203.
Ziegler, D. ( 2008a) Painful diabetic neuropathy: treatment and future aspects . Diabetes Metab Res Rev24(Suppl 1): S52-S57.
204.
Ziegler, D. ( 2008b) Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care31(Suppl 2): S255-S261.
205.
Ziegler, D., Ametov, A., Barinov, A., Dyck, P., Gurieva, I., Low, P. et al. (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care29: 2365-2370.
206.
Ziegler, D., Nowak, H. and Low, P.A. ( 2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med21: 114-121.
207.
Zin, C.S., Nissen, L.M., O’Callaghan, J.P., Duffull, S.B., Smith, M.T. and Moore, B.J. ( 2009) A randomized controlled trial of oxycodone vs placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain, in press.
208.
Zinman, L.H., Ngo, M., Ng, E.T., Nwe, K.T., Gogov, S. and Bril, V. ( 2004) Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial. Diabetes Care27: 921-924.
